Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?

Table 2

Genotypes as possible regulators of perinatal serotoninergic symptoms after in utero exposure to SSRIs—courtesy of Oberlander 2008—Molecular Psychiatry. Infant outcomes and SLC6A4 genotype: means (s.d.).

SLC6A4 genotype	ll		ls		ss
	No exposure; (𝑛=14)	SRI exposure; (𝑛=14)	No exposure; (𝑛=22)	SRI exposure; (𝑛=16)	No exposure; (𝑛=11)	SRI exposure; (𝑛=7)
Duration of prenatal SRI; exposure (days)	NA	240 (57)	NA	206 (92)	NA	231 (62)
Maternal mean daily dose of medication (𝑧 score^a)	NA	0.181 (0.138)	NA	0.299 (0.283)	NA	0.153 (0.101)
Gestational age at birth (weeks)	39.8 (1.45)	39.4 (1.48)	40.3 (1.03)	39.3 (1.61)	40.3 (1.09)	39.4 (1.44)
Birth weight (g)	3583 (594)	3416 (509)	3691 (455)	3239 (549)*	3465 (545)	3763 (367)
Birth length (cm)	52.3 (3.80)	50.1 (2.27)	51.9 (2.70)	50.5 (2.42)	52.3 (2.40)	53.1 (2.28)
Head circumference (cm)	34.8 (1.49)	34.3 (1.34)	35.2 (1.28)	34.5 (1.17)	35.0 (1.14)	35.2 (1.68)
Length of newborn stay in hospitals (h)	51.0 (22.2)	61.3 (27.9)	48.6 (25.6)	61.3 (40.9)	46.9 (27.6)	62.1 (21.4)

NA: not applicable; SRI: serotonin reuptake inhibitors. 𝑃<0.05 for differences between exposures and nonexposure within genotypes. ^aA composite drug dosage “𝑧 score” was tabulated for drug dosage to account for multiple drugs each with varying drug dose ranges.